US FDA Approves TALVEY™ (Talquetamab-Tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma

By
Bob
-
0
209
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the US FDA has granted accelerated approval of TALVEY™.
[Johnson & Johnson]
Press Release